We will make it possible for Alzheimer's patients to live an independent and active life

Alzinova AB (publ)
Interim report Q3 2023

alzinova

Summary of the period January - September 2023

Highlights - third quarter

Successful Pre-IND meeting with FDA
- Positive feedback on the clinical development program for the vaccine candidate ALZ-101.

Alzinova signed an agreement with PolyPeptide
– Expands the manufacturing capacity of the AβCC peptide for upcoming clinical studies.

The Company received positive response from EMA
–Scientific advice for the clinical development program for the vaccine candidate ALZ-101.

Key figures from the period

Three months, July – September 2023

- Net sales amounted to TSEK 0 (0).
- Loss after financial items amounted to SEK -3,549 thousand (-2,771).
- Average number of shares during the period before dilution 44,531,265 (32,419,034).
- Average number of shares during the period after dilution 44,531,265 (32,578,199).
- Earnings per share before dilution amounted to SEK -0.08 (-0.09).
- Earnings per share after dilution amounted to SEK -0.08 (-0.09).

Nine months, January – September 2023

- Net sales amounted to TSEK 0 (0).
- Loss after financial items amounted to SEK -11,749 thousand (-8,353).
- Average number of shares during the period before dilution 39,162,840 (21,650,403).
- Average number of shares during the period after dilution 39,162,840 (21,809,568).
- Earnings per share before dilution amounted to SEK -0.30 (-0.39).
- Earnings per share after dilution amounted to SEK -0.30 (-0.38).

Amounts in brackets: Corresponding period in previous year.
"the Company" or **"Alzinova"** refers to Alzinova AB with corporate identity number: 556861-8168.

Events during the third quarter 2023

- Alzinova announced on August 3 that the Company has recruited Kirsten Harting to the role of Chief Medical Officer (CMO). Kirsten Harting, who began her new position on August 14, is also a member of the Company's management team.
- On August 8, Alzinova announced that the Company had conducted a pre-IND meeting with the US Food and Drug Administration (FDA) and received positive feedback on the planned clinical development program for the vaccine candidate ALZ-101. This is a significant step in the preparations for including US study centers in future clinical studies.
- On August 25, Alzinova announced that the Company had signed an agreement with PolyPeptide Laboratories Holding (PolyPeptide) to manufacture Alzinova's peptide (AβCC) for future clinical studies.
- On September 26, Alzinova announced that the Company has received a positive response from the European Medicines Agency (EMA) regarding the planned clinical development program for the vaccine candidate ALZ-101. This means significant steps in the preparation for the inclusion of European study centers in future clinical studies.

Events after the end of the third quarter 2023

- On October 5, Alzinova announced that the Company will participate in Europe's largest life science conference BIO-Europe. The conference is a gathering place for partner meetings where the Company will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners. Furthermore, the company announced that they will present at Redeye's theme day on neurology, which was held on October 11.
- On October 24, Alzinova announced that the Company has contracted Erik Penser Bank as liquidity provider from November 1, 2023.

A word from the CEO

During the past quarter, we have continued to meet our goals to prepare the company for the next phase of clinical development.During this period, we have received positive feedback from the European and American regulatory authorities and initiated a collaboration with the peptide manufacturer PolyPeptide to secure production capacity for future clinical studies. Now we confidently look forward to top-line data for our vaccine candidate ALZ-101, which we expect to receive and present later this year.

The vaccine candidate ALZ-101 - preparing for top-line data

We are currently preparing top-line data for the phase 1 study in patients with Alzheimer's disease, which is scheduled to be presented later this year. Based on all patients who participated in the study, the top-line data will give us an overall picture of especially safety and tolerability of treatment with ALZ-101 as well as essential information on the immune response for the two different dose levels 125 µg and 250 µg. Thereafter, the analysis of the study will continue, and we will receive a full analysis and report early next year. We will present the results in discussions with potential partners and at international conferences.

In parallel, the patients will continue into the extension part of the study where all will be offered treatment with additional doses of ALZ-101. The first patient was dosed in May and the last patient in the extension part is estimated to receive their last dose in early 2024. The results from the extension part will give us valuable information on the long-term effects of ALZ-101 for phase 2 and further strengthen our position in interactions with potential partners and regulatory authorities.

These are some of the many activities that, together with the full results from the phase 1b study, will lay the foundation for us to initiate phase 2 in 2024.

Significant progress towards phase 2

As part of the preparations for the Phase 2 study, earlier this year we applied for a pre-IND meeting with the FDA and an application for scientific advice from the EMA. During this period, we have received positive feedback from the FDA and EMA on the planned development program for ALZ-101. The regulatory interactions aim to ensure that the development plan for ALZ-101 meets the regulatory requirements in both the US and Europe. By interacting with the authorities early on, we can more quickly reach important milestones in the development process with the goal of offering a new treatment for patients suffering from Alzheimer's disease. These are also important steps for the commercial development and future partnerships for ALZ-101.

During the summer, we signed an agreement with PolyPeptide, a leading peptide manufacturer, which secures our production capacity for upcoming clinical studies. A stable production with several manufacturers of the peptide is important for drug development and future commercial production. We will have a great advantage in having already secured this.

Drug candidates with "best in class" potential

In parallel with the vaccine candidate ALZ-101, we continue to develop the monoclonal antibody ALZ-201. In addition to the work that led to a patent application for a further developed form of the antibody, we continue with the preclinical development to be able to take ALZ-201 into clinic. Both drug candidates are oligomer-specific, which differentiates them from the competition and gives us "best in class" potential. Top-line data for ALZ-101 will therefore be very important for the development of ALZ-201 as well.

We look forward to the eventful period ahead with top-line data for ALZ-101 as well as BIO Europe on November 6-8 where we will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners.

We have delivered according to plan the phase 1 study, and we will soon be able to share data from the study. Our upcoming top-line data for ALZ-101 is of great interest to potential partners, shareholders, and investors alike. I look forward to sharing our progress with you!

Kristina Torfgård,
CEO of Alzinova AB

”We look forward to progressing the vaccine candidate to regulatory submissions and partnering activities with the goal of entering clinical Phase 2 in 2024”



About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's proprietary AβCC peptide technology™ enables the development of disease-modifying treatments that, with high precision, target the toxic accumulations of the peptide amyloid beta, so-called oligomers, which are central to the onset and progression of the disease. Using this technology, we can develop effective treatments which at the same time have a favourable safety profile with a lower risk of side effects. Promising preclinical results have been obtained following completion of a study on brain extracts from deceased Alzheimer's patients. The study confirms that Alzinova's unique method for specifically targeting and neutralizing toxic oligomers is effective.

Alzinova's current focus is the development of a vaccine that specifically targets and neutralizes the toxic oligomers. The vaccine is being developed as a long-acting drug for the treatment and prevention of Alzheimer's disease. The vaccine candidate ALZ-101 is in clinical development and a Phase 1b study in Alzheimer's patients was initiated in the third quarter of 2021 and fully recruited in December 2022. Based on positive interim data, the company decided in May 2023 to initiate an extension part of the ongoing clinical study. Top-line data is expected to be presented in the second half of 2023.

Based on the same technology, the Company is also developing the antibody, ALZ-201, which is currently in preclinical development. Alzinova is currently developing a humanized version of ALZ-201 for clinical phase 1 studies in patients with Alzheimer's disease. These studies are planned to start in 2024. The project portfolio for the development of disease-modifying treatments is broadened by the Company preparing the antibody to enter the clinical phase. Alzinova was founded by researchers who worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Alzinova's unique solution

- ✓ Targeted treatment that specifically targets and neutralizes the toxic peptides (so-called oligomers) that are central to the onset and development of Alzheimer's disease.
- ✓ Vaccine that stimulates the body to produce its own antibodies against oligomers (ALZ-101).
- ✓ Fast, effective and uncomplicated vaccination without long and expensive hospital stays.
- ✓ Specific treatment that is likely to have good efficacy and reduces the risk of serious side effects.
- ✓ Can start treatment early in the disease to prevent progression.
- ✓ Antibody (ALZ-201) that neutralizes the toxic oligomers and can be used as a stand-alone or as a complement to the vaccine (ALZ-101).

Other actors

- Are developing treatments that target larger accumulations of amyloid-beta, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- Non-specific treatments which are not specifically targeting and neutralizing the toxic oligomers.
- Often complicated drug treatments that require expensive hospital care.
- Targeting plaque is unlikely to be sufficiently effective and may result in serious side effects.





About Alzheimer

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous review.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease. The disease then increases sharply in prevalence in the 75-80 age range.

Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, i.e. that they exhibit efficacy in patients with Alzheimer's disease. Based on clinical data, the Company intends to identify one or more strategic partners who can acquire projects for further development and commercialization. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or through a complete acquisition of the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more global pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. Furthermore, Alzinova has secured a scalable manufacturing process for ALZ-101, which is now being prepared for a phase 2 study so that a partner can quickly start phase 2. With positive results in the Company's two drug projects ALZ-101 and ALZ-201, there are several options. One is to out-license the vaccine ALZ-101 when the phase 1b study is complete, and another option is to take this further through phase 2 and then out-license it to a partner at the end of phase 2. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is precisely on business development with several active ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 percent. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at USD 1,300 billion annually. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs has recently been approved in the United States, there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential for a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India.

[1] World Health Organization (WHO) – Facts about Dementia, March 2023.

Alzinova is developing a societal beneficial treatment



Based on Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increase societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive care.

Investment highlights

Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine to treat Alzheimer's disease. Positive interim data from the ongoing study demonstrate good safety and tolerability and a clear immunological response.

Based on the same unique technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a stand-alone or complementary treatment to the vaccine to combat Alzheimer's disease.

Data show that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) provides "best-in-class" potential, with ability to provide significantly better efficacy and a more favorable side effect.

Positive feedback from the FDA and EMA as well as other ongoing activities for the next clinical development phase, together with strong IP, make Alzinova's candidates attractive for strategic partnerships.

Financial information

Corporate structure and shareholding

Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development

During the period July-September, the Company has continued to invest in the further development of ALZ-101, which is now in clinical phase 1b, for which an extension of the study has also been initiated. The Company is preparing and investing for clinical phase. The Company has also initiated development for clinical trials of the antibody ALZ-201, with the aim of treating and also preventing the progression of Alzheimer's disease.

The Company's total expenses for the period July-September 2023 amounted to SEK 6,826 thousand (6,005). The majority of the costs, SEK 2,707 thousand (2,824), relate to research and development costs and, in particular, costs for the ongoing clinical trial, for which also the extension part has been initiated. The Company's research and development costs have been capitalised on the balance sheet. Personnel costs amounted to SEK 2,204 thousand (1,568). The higher costs are due to the increased organization with more persons employed during the year.

For the period January-September, the Company's total expenses amounted to SEK 25,699 thousand (21,570). The cost increase mainly due to higher research and development costs, with the clinical study ongoing during the whole of this year, increased costs from the interaction with regulatory authorities, and the increased organization costs starting from the fourth quarter 2022 with more persons employed.

Cash flow from operating activities during the period July-September 2023 amounted to SEK -375 thousand (-1,836). The lower cash flow depends mainly on deferment of payment for social costs to the tax authority, SEK 3,073 thousand, applied for retroactively. The cash flow from the investment activities represents expenditures on ongoing capitalized research and development costs, and amounted during same period to SEK -3,300 thousand (-3,240). Cash flow from financing activities amounted to SEK 0 thousand (-107).

For the period January-September 2023 in total, the cash flow from operating activities amounted to SEK -9,948 thousand (-6,877). The cash flow depends to a large extent to costs described above. The cash flow from investment activities amounted to SEK -13,990 thousand (-13,231). Cash flow from financing activities amounted to SEK 24,805 thousand (30,150) where shares were issued through the subscription warrants in May this year, and where a preferred rights issue was carried through in June previous year.

At the end of the period (30 September, 2023), the Company's equity amounted to approximately SEK 118.6 million with an equity ratio of 93.9% (SEK 110.3 million and 95.9% respectively), and total cash balance amounted to approximately SEK 33 million (39).

Continuous work is underway on various financing options, to further strengthen the Company's financial position.

Risk factors

Alzinova maintains procedures to continuously identify and manage risk factors. A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2022.

Auditor's review

This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report

The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, November 2, 2023
Alzinova AB (publ)

Income statement

(TSEK)	2023-07-01 2023-09-30 3 months	2022-07-01 2022-09-30 3 months	2023-01-01 2023-09-30 9 months	2022-01-01 2022-09-30 9 months	2022-01-01 2022-12-31 12 months
Net sales	-	-	-	-	-
Own work capitalized	3,300	3,240	13,990	13,231	16,633
	3,300	**3,240**	**13,990**	**13,231**	**16,633**
Operating expenses					
Other external expenses	-4,625	-4,437	-19,506	-16,884	-23,033
Personnel expenses	-2,204	-1,568	-6,193	-4,686	-6,687
Operating result	**-3,529**	**-2,765**	**-11,709**	**-8,339**	**-13,087**
Result from financial items					
Interest income	0	0	1	0	18
Interest expenses	-20	-6	-41	-14	-19
Result after financial items	**-3,549**	**-2,771**	**-11,749**	**-8,353**	**-13,088**
Result before tax	**-3,549**	**-2,771**	**-11,749**	**-8,353**	**-13,088**
Result for the period	**-3,549**	**-2,771**	**-11,749**	**-8,353**	**-13,088**

Balance sheet

(TSEK)	2023-09-30	2022-09-30	2022-12-31
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	90,639	73,246	76,649
Patent	1,632	1,632	1,632
	92,271	**74,878**	**78,281**
Total fixed assets	**92,271**	**74,878**	**78,281**
Current assets			
Short term receivables			
Tax receivables	223	172	206
Other receivables	594	661	630
Prepaid expenses and accrued income	335	371	466
	1,152	**1,204**	**1,302**
Cash and cash receivables	**32,905**	**38,877**	**32,038**
Total current assets	**34,057**	**40,081**	**33,340**
TOTAL ASSETS	**126,328**	**114,959**	**111,621**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	11,712	8,526	8,526
Fund for development costs	88,576	71,177	74,586
	100,288	**79,703**	**83,112**
Unrestricted equity			
Share premium	166,264	144,645	144,645
Retained result	-136,214	-105,727	-109,136
Results for the year/period	-11,749	-8,353	13,088
	18,301	**30,565**	**22,421**
Total equity	**118,589**	**110,268**	**105,533**
Long term liabilities			
Other long term liabilities	800	800	800
	800	**800**	**800**
Short term liabilities			
Accounts payable	2,015	1,990	3,170
Other current liabilities	3,260	562	723
Accrued expenses and prepaid income	1,664	1,339	1,395
	6,939	**3,891**	**5,288**
TOTAL EQUITY AND LIABILITIES	**126,328**	**114,959**	**111,621**

Change in equity, condensed

(TSEK) 2023-01-01 2023-09-30 9 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186		23,098		26,284
Transaction costs share issue			-1,479		-1,479
Transfer within equity		13,990		-13,990	0
Net result for the period				-11,749	11,749
At the end of the period	**11,712**	**88,576**	**166,264**	**-147,963**	**118,589**

(TSEK) 2022-01-01 2022-09-30 9 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**4,149**	**57,946**	**118,873**	**-92,496**	**88,472**
Share issue	4,377		32,482	0	36,859
Transaction costs share issue			-6,710		-6,710
Transfer within equity		13,231		-13,231	0
Net result for the period				-8,353	-8,353
At the end of the period	**8,526**	**71,177**	**144,645**	**-114,080**	**110,268**

(TSEK) 2022-01-01 2022-12-31 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**4,149**	**57,947**	**118,873**	**-92,497**	**88,472**
Share issue	4,377		32,482		36,859
Transaction costs share issue			-6,710		-6,710
Transfer within equity		16,639		-16,639	0
Net result for the year				-13,088	-13,088
At the end of the year	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**

Cash flow statement, condensed

(TSEK)	2023-07-01 2023-09-30 3 months	2022-07-01 2022-09-30 3 months	2023-01-01 2023-09-30 9 months	2022-01-01 2022-09-30 9 months	2022-01-01 2022-12-31 12 months
Operating activities					
Result after financial items	-3,549	-2,771	-11,749	-8,353	-13,088
Adjustments for items not included in cash flow	-	-	-	-	-
Cash flow from operating activities before change in working capital	**-3,549**	**-2,771**	**-11,749**	**-8,353**	**-13,088**
Cash flow from change in working capital					
Increase (-)/Decrease (+) in operating receivables	35	310	150	5	-94
Increase (+)/Decrease (-) in operating liabilities	3,139	625	1,651	1,471	2,868
Cash flow from operating activities	**-375**	**-1,836**	**-9,948**	**-6,877**	**-10,314**
Investing activities					
Acquisition of intangible fixed assets	-3,300	-3,240	-13,990	-13,231	-16,633
Cash flow from investing activities	**-3,300**	**-3,240**	**-13,990**	**-13,231**	**-16,633**
Financing activities					
Share issue	0	-	26,284	36,860	36,860
Transaction costs share issue	0	-107	-1,479	-6,710	-6,710
Cash flow from financing activities	**0**	**-107**	**24,805**	**30,150**	**30,150**
Cash flow for the period	**-3,675**	**-5,183**	**867**	**10,042**	**3,203**
Cash and cash equivalents at the beginning of the period	**36,580**	**44,060**	**32,038**	**28,835**	**28,835**
Cash and cash equivalents at the end of the period	**32,905**	**38,877**	**32,905**	**38,877**	**32,038**

The share

Alzinova's share was listed on the Spotlight Stock Market on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of September 30, 2023, the number of shares in Alzinova amounted to 44,531,265 (32,419,034 as of September 30, 2022).

Share-based incentive programs

Currently there are no long-term share-based incentive programs in the Company.

Rights issue

During April 2023 a total of 12,112,231 subscription warrants of series TO3 where exercised for signing shares, which meant that the Company's shares increased with 12,112,231 shares to a total of 44,531,265 shares and a total share capital of SEK 11,711,723. In total, the share issue contributed to the Company with a net of around SEK 24.8 million after deduction of costs SEK 1.5 million. For shareholders who did not exercise their warrants, the dilution amounted to approximately 27.2% based on the total number of shares in the Company.

Largest owners per September 30, 2023

Owner	Number of shares	Capital %
Maida Vale Capital AB	6,747,686	15.15%
Försäkrings AB Avanza pension	3,223,681	7.24%
Nordnet Pensionsförsäkring AB	2,229,751	5.01%
Patrik Ahlvin	1,004,750	2.26%
Sara Gjertz	877,303	1.97%
Ålandsbanken, for owner	746,499	1.67%
MIVAC Development AB	711,787	1.60%
Özlem Erdogdu Gül	671,316	1.51%
MGC Capital Ltd	604,171	1.36%
Moll Invest AB	600,080	1.35%
Total 10 largest shareholders	**17,417,024**	**39.12%**
Total other shareholders	27,114,241	60.88%
Total all shareholders	**44,531,265**	**100.00%**

Financial calendar

2023

Interim report 1, 2023	2023-05-17
Annual general meeting 2023	2023-05-30
Interim report 2, 2023	2023-08-17
Interim report 3, 2023	2023-11-02
Year-end report, 2023	2024-02-28

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

For further information, please contact:

Kristina Torfgård, CEO, kristina.torfgard@alzinova.com, telephone +46 708 467975
Håkan Skogström, CFO, hakan.skogstrom@alzinova.com, telephone +46 705 850859
or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
EMA	European Medicines Agency
FDA	The United States Food and Drug Administration
IP	Intellectual properties, for example patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Neurotoxic	Dangerous or poisonous to the brain
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42
Pre-IND meeting	Regulatory advice from the FDA regarding product development programs

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Pepparedsleden 1, SE-431 83,
Mölndal, Sweden

alzinova